PubMed Health⌕ Search

Biomedical subjects

R Place

Publications and source records attributed to R Place.

5 recordsLinked to original sources

IkappaBbeta-related proteins in normal and transformed colonic epithelial cells.

The transcription factor nuclear factor-kappaB (NF-kappaB) regulates genes that can influence cell proliferation, apoptosis, and inflammatory responses. Since these events can contribute to carcinogenesis, we examined the expression of NF-kappaB inhibitory proteins (IkappaBs) in normal and transformed colonic epithelial cells. Immunohistochemical analysis of the mouse colon revealed a high level of IkappaBbeta expression in epithelial cells relative to the rest of the tissue, whereas IkappaBalpha was found primarily in cells of the lamina propria. Mouse colon tumors showed a similar cell-specific staining pattern. Immunoblot analysis of IkappaBbeta from mouse colonocytes and the human HT-29 colon cancer cell line indicated that most of the IkappaBbeta in these cells was similar to the C-terminal-truncated IkappaBbeta2 isoform. Cell fractionation studies were consistent with IkappaBbeta being a major regulator of p65-p50 NF-kappaB complexes in HT-29 cells. Interestingly, two larger proteins specifically recognized by IkappaBbeta antibodies (p106 and p112) were found in HT-29 cells and in colon tissue of carcinogen-exposed mice. The p106 and p112 proteins bound to NF-kappaB, and their levels changed during the transient interleukin-1beta activation of NF-kappaB in HT-29 cells. Evidence was obtained indicating that p106 and p112 are stably ubiquitinated forms of IkappaBbeta. We propose that deficiencies in the proteasomal degradation of IkappaBbeta lead to p106 and p112 accumulation, which in turn alter NF-kappaB regulation in colon cancer cells.

Animals↗

Tobacco.

Explore the source record for details and available documents.

Adolescent↗

Stereotactic breast biopsy is accurate, minimally invasive, and cost effective.

BACKGROUND: We reviewed our experience with stereotactic core needle breast biopsy (SCNBB) for accuracy, complication rate, and staging profile of malignancies diagnosed. METHODS: Since March 1993, 530 stereotactic biopsies were performed. Of these, 25 cases underwent stereotactic core needle biopsy with subsequent wire-guided biopsy. RESULTS: In 25 patients with stereotactic and open biopsy, there was an accuracy for SCNBB of 96%. The number of biopsies rose from 100 to 250 biopsies annually, with an equivalent pre-test positive predictive value for mammography (17% to 19% historical versus 20% with SCNBB). The total number of de novo cancer diagnoses have increased from a mean of 57 to a mean of 71 annually. The percentage of tumors in situ, stage I or stage II, has increased from 60% to 69%. CONCLUSIONS: Stereotactic core needle biopsy combines a high accuracy with a low complication rate. Its aggressive application for tissue diagnosis in suspicious nonpalpable mammographic lesions has increased the proportion of early (in situ and T1 or T2) tumors discovered, and increased the total number of breast cancers diagnosed.

Biopsy, Needle↗

Fine needle aspiration in the clinical management of mammary masses.

The role of fine needle aspiration (FNA) for clinical decision-making in patients with nodules of the breast remains in evolution. We retrospectively studied FNA outcomes in 183 patients, stratified by decades of age, to determine the reliability of FNA cytologic examination. Using Bayesian analysis, the predictive value of a positive FNA for women more than 60 years of age is 98 to 99 percent. In women 41 to 60 years of age, those with a first-degree relative with carcinoma of the breast and those with a prior biopsy with increased risk have an 88 to 95 percent likelihood of carcinoma. In women younger than 41 years of age, this likelihood decreases to 65 percent. Additionally, the probability of a lump being carcinoma, given the FNA was negative, ranges from 3 to 80 percent. Therefore, biopsy of a dominant nodule should not be deferred based only on a negative FNA. We can conclude that women 61 years of age or older could be counseled for definitive care at the first operation. Women 41 to 60 years of age, those with a positive family history or those with a past biopsy with increased risk, could be counseled for definitive therapy, but have the diagnosis confirmed with frozen section. Women less than 40 years of age without other risk factors receive no diagnostic benefit from FNA and should only be evaluated with open biopsy.

Adult↗